[1]
|
Ceci, C., et al. (2020) Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers (Basel), 12, Article 3401.
https://doi.org/10.3390/cancers12113401
|
[2]
|
Liu, Z., et al. (2019) Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells. Cell, 178, 1509- 1525e19. https://doi.org/10.1016/j.cell.2019.08.009
|
[3]
|
Ginhoux, F., et al. (2010) Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. Science, 330, 841-845. https://doi.org/10.1126/science.1194637
|
[4]
|
Guilliams, M., et al. (2013) Alveolar Macrophages Develop from Fetal Monocytes That Differentiate into Long-Lived Cells in the First Week of Life via GM-CSF. Journal of Experimental Medicine, 210, 1977-1992.
https://doi.org/10.1084/jem.20131199
|
[5]
|
Bain, C.C., et al. (2014) Constant Replenishment from Circulating Monocytes Maintains the Macrophage Pool in the Intestine of Adult Mice. Nature Immunology, 15, 929-937. https://doi.org/10.1038/ni.2967
|
[6]
|
Liu, Y. and Cao, X. (2015) The Origin and Function of Tumor-Associated Macrophages. Cellular & Molecular Immunology, 12, 1-4. https://doi.org/10.1038/cmi.2014.83
|
[7]
|
Biswas, S.K. and Mantovani, A. (2010) Macrophage Plasticity and Interaction with Lymphocyte Subsets: Cancer as a Paradigm. Nature Immunology, 11, 889-896. https://doi.org/10.1038/ni.1937
|
[8]
|
Bottazzi, B., et al. (1983) Regulation of the Macrophage Content of Neoplasms by Chemoattractants. Science, 220, 210-212. https://doi.org/10.1126/science.6828888
|
[9]
|
Qian, B.Z. and Pollard, J.W. (2010) Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell, 141, 39-51.
https://doi.org/10.1016/j.cell.2010.03.014
|
[10]
|
Hambardzumyan, D., Gutmann, D.H. and Kettenmann, H. (2016) The Role of Microglia and Macrophages in Glioma Maintenance and Progression. Nature Neuroscience, 19, 20-27. https://doi.org/10.1038/nn.4185
|
[11]
|
Qian, B.Z., et al. (2011) CCL2 Recruits Inflammatory Monocytes to Facilitate Breast-Tumour Metastasis. Nature, 475, 222-225. https://doi.org/10.1038/nature10138
|
[12]
|
Loyher, P.L., et al. (2018) Macrophages of Distinct Origins Contribute to Tumor Development in the Lung. Journal of Experimental Medicine, 215, 2536-2553. https://doi.org/10.1084/jem.20180534
|
[13]
|
Zhu, Y., et al. (2017) Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity, 47, 323-338.e6.
https://doi.org/10.1016/j.immuni.2017.08.018
|
[14]
|
Bowman, R.L., et al. (2016) Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Reports, 17, 2445-2459. https://doi.org/10.1016/j.celrep.2016.10.052
|
[15]
|
Chen, Z., et al. (2017) Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Research, 77, 2266-2278. https://doi.org/10.1158/0008-5472.CAN-16-2310
|
[16]
|
DeNardo, D.G. and Ruffell, B. (2019) Macrophages as Regulators of Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 19, 369-382. https://doi.org/10.1038/s41577-019-0127-6
|
[17]
|
Kumar, V., et al. (2016) CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity, 44, 303-315.
https://doi.org/10.1016/j.immuni.2016.01.014
|
[18]
|
Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity, 41, 49-61.
https://doi.org/10.1016/j.immuni.2014.06.010
|
[19]
|
Pollard, J.W. (2009) Trophic Macrophages in Development and Disease. Nature Reviews Immunology, 9, 259-270.
https://doi.org/10.1038/nri2528
|
[20]
|
Morandi, F. and Pistoia, V. (2014) Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Frontiers in Immunology, 5, Article 394. https://doi.org/10.3389/fimmu.2014.00394
|
[21]
|
Santarpia, M. and Karachaliou, N. (2015) Tumor Immune Microenvironment Characterization and Response to Anti-PD-1 Therapy. Cancer Biology & Medicine, 12, 74-78.
|
[22]
|
Buchbinder, E.I. and Desai, A. (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology, 39, 98-106. https://doi.org/10.1097/COC.0000000000000239
|
[23]
|
Mellor, A.L., et al. (2002) Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses. The Journal of Immunology, 168, 3771-3776. https://doi.org/10.4049/jimmunol.168.8.3771
|
[24]
|
Mbongue, J.C., et al. (2015) The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel), 3, 703-729. https://doi.org/10.3390/vaccines3030703
|
[25]
|
Mantovani, A., et al. (2008) Cancer-Related Inflammation. Nature, 454, 436-444. https://doi.org/10.1038/nature07205
|
[26]
|
Cersosimo, F., et al. (2020) Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. International Journal of Molecular Sciences, 21, Article 5207. https://doi.org/10.3390/ijms21155207
|
[27]
|
Mantovani, A. and Allavena, P. (2015) The Interaction of Anticancer Therapies with Tumor-Associated Macrophages. Journal of Experimental Medicine, 212, 435-445. https://doi.org/10.1084/jem.20150295
|
[28]
|
Bonavita, E., et al. (2015) Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Advances in Cancer Research, 128, 141-171. https://doi.org/10.1016/bs.acr.2015.04.013
|
[29]
|
Leek, R.D., et al. (1996) Association of Macrophage Infiltration with Angiogenesis and Prognosis in Invasive Breast Carcinoma. Cancer Research, 56, 4625-4629.
|
[30]
|
Tian, Y., Ke, Y. and Ma, Y. (2020) High Expression of Stromal Signatures Correlated with Macrophage Infiltration, Angiogenesis and Poor Prognosis in Glioma Microenvironment. PeerJ, 8, e9038. https://doi.org/10.7717/peerj.9038
|
[31]
|
Murdoch, C., et al. (2008) The Role of Myeloid Cells in the Promotion of Tumour Angiogenesis. Nature Reviews Cancer, 8, 618-631. https://doi.org/10.1038/nrc2444
|
[32]
|
Su, B., et al. (2021) Let-7d Inhibits Intratumoral Macrophage M2 Polarization and Subsequent Tumor Angiogenesis by Targeting IL-13 and IL-10. Cancer Immunology, Immunotherapy, 70, 1619-1634.
https://doi.org/10.21203/rs.3.rs-27516/v1
|
[33]
|
Smeester, B.A., et al. (2020) PLX3397 Treatment Inhibits Constitutive CSF1R-Induced Oncogenic ERK Signaling, Reduces Tumor Growth, and Metastatic Burden in Osteosarcoma. Bone, 136, Article ID: 115353.
https://doi.org/10.1016/j.bone.2020.115353
|
[34]
|
Tap, W.D., et al. (2015) Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. The New England Journal of Medicine, 373, 428-437. https://doi.org/10.1056/NEJMoa1411366
|
[35]
|
Molena, B., et al. (2011) Synovial Colony-Stimulating Factor-1 mRNA Expression in Diffuse Pigmented Villonodular Synovitis. Clinical and Experimental Rheumatology, 29, 547-550.
|
[36]
|
Ries, C.H., et al. (2014) Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 25, 846-859. https://doi.org/10.1016/j.ccr.2014.05.016
|
[37]
|
Butowski, N., et al. (2016) Orally Administered Colony Stimulating Factor 1 Receptor Inhibitor PLX3397 in Recurrent Glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium Phase II Study. Neuro-Oncology, 18, 557-564. https://doi.org/10.1093/neuonc/nov245
|
[38]
|
von Tresckow, B., et al. (2015) An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research, 21, 1843-1850.
https://doi.org/10.1158/1078-0432.CCR-14-1845
|
[39]
|
Pyonteck, S.M., et al. (2013) CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression. Nature Medicine, 19, 1264-1272. https://doi.org/10.1038/nm.3337
|
[40]
|
Cassier, P.A., et al. (2015) CSF1R Inhibition with Emactuzumab in Locally Advanced Diffuse-Type Tenosynovial Giant Cell Tumours of the Soft Tissue: A Dose-Escalation And Dose-Expansion Phase 1 Study. The Lancet Oncology, 16, 949-956. https://doi.org/10.1016/S1470-2045(15)00132-1
|
[41]
|
Piaggio, F., et al. (2016) A Novel Liposomal Clodronate Depletes Tumor-Associated Macrophages in Primary and Metastatic Melanoma: Anti-Angiogenic and Anti-Tumor Effects. The Journal of Controlled Release, 223, 165-177.
https://doi.org/10.1016/j.jconrel.2015.12.037
|
[42]
|
Hiraoka, K., et al. (2008) Inhibition of Bone and Muscle Metastases of Lung Cancer Cells by a Decrease in the Number of Monocytes/Macrophages. Cancer Science, 99, 1595-1602. https://doi.org/10.1111/j.1349-7006.2008.00880.x
|
[43]
|
Gazzaniga, S., et al. (2007) Targeting Tumor-Associated Macrophages and Inhibition of MCP-1 Reduce Angiogenesis and Tumor Growth in a Human Melanoma Xenograft. Journal of Investigative Dermatology, 127, 2031-2041.
https://doi.org/10.1038/sj.jid.5700827
|
[44]
|
Zhou, Y., et al. (2020) Liposomal Clodronate Combined with Cisplatin or Sorafenib Inhibits Hepatocellular Carcinoma Cell Proliferation, Migration and Invasion by Suppressing FOXQ1 Expression. Cellular and Molecular Biology (Noisy-le-Grand), 66, 49-54. https://doi.org/10.14715/cmb/2019.66.1.8
|
[45]
|
Zhang, W., et al. (2010) Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects. Clinical Cancer Research, 16, 3420-3430.
https://doi.org/10.1158/1078-0432.CCR-09-2904
|
[46]
|
Cassetta, L. and Pollard, J.W. (2018) Targeting Macrophages: Therapeutic Approaches in Cancer. Nature Reviews Drug Discovery, 17, 887-904. https://doi.org/10.1038/nrd.2018.169
|
[47]
|
Deshmane, S.L., et al. (2009) Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. Journal of Interferon & Cytokine Research, 29, 313-326. https://doi.org/10.1089/jir.2008.0027
|
[48]
|
Yoshimura, T. (2017) The Production of Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 in Tumor Microenvironments. Cytokine, 98, 71-78. https://doi.org/10.1016/j.cyto.2017.02.001
|
[49]
|
Li, L., et al. (2018) High Levels of CCL2 or CCL4 in the Tumor Microenvironment Predict Unfavorable Survival in Lung Adenocarcinoma. Thoracic Cancer, 9, 775-784. https://doi.org/10.1111/1759-7714.12643
|
[50]
|
De la Fuente Lopez, M., et al. (2018) The Relationship between Chemokines CCL2, CCL3, and CCL4 with the Tumor Microenvironment and Tumor-Associated Macrophage Markers in Colorectal Cancer. Tumor Biology, 40.
https://doi.org/10.1177/1010428318810059
|
[51]
|
Avila, M.A. and Berasain, C. (2019) Targeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool Emerging Out of the Box against Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 7, 293-294.
https://doi.org/10.1016/j.jcmgh.2018.11.002
|
[52]
|
Zheng, Y., et al. (2021) Epigenetic Silencing of Chemokine CCL2 Represses Macrophage Infiltration to Potentiate Tumor Development in Small Cell Lung Cancer. Cancer Letters, 499, 148-163.
https://doi.org/10.1016/j.canlet.2020.11.034
|
[53]
|
Steinberger, K.J., et al. (2020) Stress-Induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma. Cancer Prevention Research (Phila), 13, 747-760.
https://doi.org/10.1158/1940-6207.CAPR-19-0370
|
[54]
|
Yao, M., et al. (2017) Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts. Translational Oncology, 10, 734-743.
https://doi.org/10.1016/j.tranon.2017.06.009
|
[55]
|
Loberg, R.D., et al. (2007) CCL2 as an Important Mediator of Prostate Cancer Growth in Vivo through the Regulation of Macrophage Infiltration. Neoplasia, 9, 556-562. https://doi.org/10.1593/neo.07307
|
[56]
|
Bonapace, L., et al. (2014) Cessation of CCL2 Inhibition Accelerates Breast Cancer Metastasis by Promoting Angiogenesis. Nature, 515, 130-133. https://doi.org/10.1038/nature13862
|
[57]
|
Hitchcock, J.R. and Watson, C.J. (2015) Anti-CCL2: Building a Reservoir or Opening the Floodgates to Metastasis? Breast Cancer Research, 17, Article No. 68. https://doi.org/10.1186/s13058-015-0573-4
|
[58]
|
Lebrecht, A., et al. (2004) Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer. Tumor Biology, 25, 14-17. https://doi.org/10.1159/000077718
|
[59]
|
Loberg, R.D., et al. (2007) Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression in Vivo. Cancer Research, 67, 9417-9424. https://doi.org/10.1158/0008-5472.CAN-07-1286
|
[60]
|
Moisan, F., et al. (2014) Enhancement of Paclitaxel and Carboplatin Therapies by CCL2 Blockade in Ovarian Cancers. Molecular Oncology, 8, 1231-1239. https://doi.org/10.1016/j.molonc.2014.03.016
|
[61]
|
Nywening, T.M., et al. (2016) Targeting Tumour-Associated Macrophages with CCR2 Inhibition in Combination with FOLFIRINOX in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single-Centre, Open-Label, Dose-Finding, Non-Randomised, Phase 1b Trial. The Lancet Oncology, 17, 651-662.
https://doi.org/10.1016/S1470-2045(16)00078-4
|
[62]
|
Chen, J., et al. (2017) SLAMF7 Is Critical for Phagocytosis of Haematopoietic Tumour Cells via Mac-1 Integrin. Nature, 544, 493-497. https://doi.org/10.1038/nature22076
|
[63]
|
Xiao, Z., et al. (2015) Antibody Mediated Therapy Targeting CD47 Inhibits Tumor Progression of Hepatocellular Carcinoma. Cancer Letters, 360, 302-309. https://doi.org/10.1016/j.canlet.2015.02.036
|
[64]
|
Edris, B., et al. (2012) Antibody Therapy Targeting the CD47 Protein Is Effective in a Model of Aggressive Metastatic Leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 109, 6656-6661.
https://doi.org/10.1073/pnas.1121629109
|
[65]
|
Weiskopf, K., et al. (2016) CD47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small- Cell Lung Cancer. Journal of Clinical Investigation, 126, 2610-2620. https://doi.org/10.1172/JCI81603
|
[66]
|
Liu, R., et al. (2017) CD47 Promotes Ovarian Cancer Progression by Inhibiting Macrophage Phagocytosis. Oncotarget, 8, 39021-39032. https://doi.org/10.18632/oncotarget.16547
|
[67]
|
Wu, Z., et al. (2019) Identification of Glutaminyl Cyclase Isoenzyme isoQC as a Regulator of SIRPalpha-CD47 Axis. Cell Research, 29, 502-505. https://doi.org/10.1038/s41422-019-0177-0
|
[68]
|
Logtenberg, M.E.W., et al. (2019) Glutaminyl Cyclase Is an Enzymatic Modifier of the CD47-SIRPalpha Axis and a Target for Cancer Immunotherapy. Nature Medicine, 25, 612-619. https://doi.org/10.1038/s41591-019-0356-z
|
[69]
|
Ansell, S.M., et al. (2021) Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research, 27, 2190-2199.
|
[70]
|
Petrova, P.S., et al. (2017) TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clinical Cancer Research, 23, 1068-1079.
https://doi.org/10.1158/1078-0432.CCR-16-1700
|
[71]
|
Kaczanowska, S., Joseph, A.M. and Davila, E. (2013) TLR Agonists: Our Best Frenemy in Cancer Immunotherapy. Journal of Leukocyte Biology, 93, 847-863. https://doi.org/10.1189/jlb.1012501
|
[72]
|
Le Mercier, I., et al. (2013) Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment. Cancer Research, 73, 4629-4640. https://doi.org/10.1158/0008-5472.CAN-12-3058
|
[73]
|
Singh, M., et al. (2014) Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation. The Journal of Immunology, 193, 4722-4731. https://doi.org/10.4049/jimmunol.1401160
|
[74]
|
Vacchelli, E., et al. (2016) Trial Watch: Immunotherapy plus Radiation Therapy for Oncological Indications. Oncoimmunology, 5, e1214790. https://doi.org/10.1080/2162402X.2016.1214790
|
[75]
|
Menzies, S., Mc Menamin, M. and Barry, R. (2017) Lentigo Maligna Successfully Treated with Combination Therapy of Topical Tazarotene and Imiquimod. Clinical and Experimental Dermatology, 42, 468-470.
https://doi.org/10.1111/ced.13053
|
[76]
|
Klichinsky, M., et al. (2020) Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Nature Biotechnology, 38, 947-953. https://doi.org/10.1038/s41587-020-0462-y
|
[77]
|
Zhang, L., et al. (2020) Pluripotent Stem Cell-Derived CAR-Macrophage Cells with Antigen-Dependent Anti-Cancer Cell Functions. Journal of Hematology & Oncology, 13, Article No. 153. https://doi.org/10.1186/s13045-020-00983-2
|
[78]
|
Hirsch, E., et al. (2000) Central Role for G Protein-Coupled Phosphoinositide 3-Kinase Gamma in Inflammation. Science, 287, 1049-1053. https://doi.org/10.1126/science.287.5455.1049
|
[79]
|
Kaneda, M.M., et al. (2016) PI3Kgamma Is a Molecular Switch That Controls Immune Suppression. Nature, 539, 437-442. https://doi.org/10.1038/nature19834
|